Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP

Abstract

This study aimed to investigate and compare exosomal miR-155, let-7g and let-7i levels as a noninvasive biomarker among patients with refractory/relapsed or responsive DLBCL after R-CHOP treatment and patients receiving R-CHOP. Plasma was collected and exosomes were isolated from plasma. Exosomes confirmed by zeta-seizer, electron microscope, and western blot. Exosomes concentration was investigated by BCA assay. MiR-155, let-7g and let-7i levels were evaluated in plasma-derived exosomes by real-time PCR. Plasma IFN-γ and IL-4 level were measured by ELISA assay. We observed the significant increase in the exosomal miR-155 levels (p = .002) and exosomes concentration (p = .001) in refractory/relapsed patients compared to responsive patients and patients receiving R-CHOP. No association was not observed between exosomal miR-155 levels and IPI and disease stage. The significant decrease in IFN-γ levels was observed in patients receiving R-CHOP compared to refractory/relapsed or responsive patients (p=.001). Therefore, exosomal miR-155 might be useful as potential prognostic biomarkers to predict response to treatment in DLBCL patients.

Keywords:

• Diffuse large B-cell lymphoma (DLBCL)
• exosomes
• let-7g
• let-7i
• miR-155

Acknowledgments

The authors thank the cooperation of Dr. Mohsen Khani and nurses of Saba oncology clinic and Alzahra Hospital.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http:\\10.1080/10428194.2018.1563692.

Additional information

Funding

This work was supported by Isfahan University of Medical Sciences.